• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.

作者信息

Pedersen S S, Koch C, Høiby N, Rosendal K

出版信息

J Antimicrob Chemother. 1986 Apr;17(4):505-16. doi: 10.1093/jac/17.4.505.

DOI:10.1093/jac/17.4.505
PMID:3086274
Abstract

Early in 1983 an epidemic of a Pseudomonas aeruginosa resistant to aminoglycosides, carbenicillin, ureidopenicillins, ceftazidime, cefsulodin and imipenem occurred in a cystic fibrosis centre. Most of the epidemic could be attributed to a specific nosocomial strain by means of O-grouping and phage-typing. This strain was present in the centre at a low frequency in 1973 and developed resistance during courses of chemotherapy. The epidemic was stopped by isolating patients with the resistant strains. Restrictive and selective use of antibiotics have not been sufficient to eradicate the resistant strains, which persist in 42% of the patients. The extensive use of the third generation cephalosporins in the clinic is probably responsible for inducing and selecting for the resistant strains. Clustering of patients in the centre has facilitated the spread. First-line use of older beta-lactam antibiotics, close bacteriological monitoring and prompt isolation of patients with resistant strains are recommended.

摘要

相似文献

1
An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.
J Antimicrob Chemother. 1986 Apr;17(4):505-16. doi: 10.1093/jac/17.4.505.
2
Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.β-内酰胺耐药铜绿假单胞菌在一家囊性纤维化诊所的传播。
Lancet. 1996 Sep 7;348(9028):639-42. doi: 10.1016/S0140-6736(96)05169-0.
3
Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.用头孢他啶和妥布霉素治疗囊性纤维化患者的慢性铜绿假单胞菌感染。
Scand J Infect Dis. 1983;15(3):271-6. doi: 10.3109/inf.1983.15.issue-3.07.
4
Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis.抗铜绿假单胞菌化疗对囊性纤维化的细菌学影响。
Infection. 1987;15(5):403-6. doi: 10.1007/BF01647753.
5
Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.铜绿假单胞菌在使用新型β-内酰胺类抗生素治疗期间对β-内酰胺类抗生素产生耐药性。
Chemioterapia. 1985 Feb;4(1):95-101.
6
Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.亚胺培南/西司他丁与妥布霉素联合治疗囊性纤维化患者多重耐药铜绿假单胞菌感染
J Antimicrob Chemother. 1987 Jan;19(1):101-7. doi: 10.1093/jac/19.1.101.
7
Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance.由多重耐药性铜绿假单胞菌P12菌株引起的医院感染暴发:头孢吡肟-阿米卡星治疗的疗效及β-内酰胺耐药性分析
J Clin Microbiol. 2001 Jun;39(6):2072-8. doi: 10.1128/JCM.39.6.2072-2078.2001.
8
The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?囊性纤维化患者呼吸道假单胞菌感染的治疗:用什么药物及采用何种方式?
Drugs. 2000 Nov;60(5):1053-64. doi: 10.2165/00003495-200060050-00006.
9
Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center.在一家儿科囊性纤维化中心就诊的患者之间耐黏菌素铜绿假单胞菌的传播。
Pediatr Pulmonol. 2002 Oct;34(4):257-61. doi: 10.1002/ppul.10166.
10
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.丹麦囊性纤维化中心在二十年抗铜绿假单胞菌治疗期间铜绿假单胞菌抗生素耐药性的发展。
APMIS. 1994 Sep;102(9):674-80.

引用本文的文献

1
Cystic fibrosis and the clinical biofilm revolution A survey of the Danish CF Center's contribution.囊性纤维化与临床生物膜革命:丹麦囊性纤维化中心贡献的调查
Biofilm. 2024 Dec 20;9:100246. doi: 10.1016/j.bioflm.2024.100246. eCollection 2025 Jun.
2
Glycerol metabolism impacts biofilm phenotypes and virulence in via the Entner-Doudoroff pathway.甘油代谢通过恩特纳-杜德洛夫途径影响生物膜表型和毒力。
mSphere. 2024 Apr 23;9(4):e0078623. doi: 10.1128/msphere.00786-23. Epub 2024 Mar 19.
3
PtsN in Pseudomonas aeruginosa Is Phosphorylated by Redundant Upstream Proteins and Impacts Virulence-Related Genes.
铜绿假单胞菌中的 PtsN 被冗余上游蛋白磷酸化,影响与毒力相关的基因。
J Bacteriol. 2023 May 25;205(5):e0045322. doi: 10.1128/jb.00453-22. Epub 2023 Apr 19.
4
Pseudomonas aeruginosa Alters Peptidoglycan Composition under Nutrient Conditions Resembling Cystic Fibrosis Lung Infections.铜绿假单胞菌在类似于囊性纤维化肺部感染的营养条件下改变肽聚糖组成。
mSystems. 2022 Jun 28;7(3):e0015622. doi: 10.1128/msystems.00156-22. Epub 2022 May 12.
5
International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives.与ERN-LUNG PCD核心网络及患者代表合作制定的原发性纤毛运动障碍感染预防与控制的国际BEAT-PCD共识声明。
ERJ Open Res. 2021 Aug 2;7(3). doi: 10.1183/23120541.00301-2021. eCollection 2021 Jul.
6
: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors.一种具有适应性毒力因子武器库的大胆病原体。
Int J Mol Sci. 2021 Mar 18;22(6):3128. doi: 10.3390/ijms22063128.
7
Carbapenem-Resistant Pseudomonas aeruginosa in Chronic Lung Infection: Current Resistance Profile and Hypermutability in Patients with Cystic Fibrosis.慢性肺部感染中耐碳青霉烯类铜绿假单胞菌:囊性纤维化患者的当前耐药情况及高突变性
Curr Microbiol. 2021 Feb;78(2):696-704. doi: 10.1007/s00284-020-02337-0. Epub 2021 Jan 6.
8
Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.囊性纤维化中克隆铜绿假单胞菌感染的流行病学、生物学和影响。
Clin Microbiol Rev. 2018 Aug 29;31(4). doi: 10.1128/CMR.00019-18. Print 2018 Oct.
9
Risk of Bacterial Transmission in Bronchiectasis Outpatient Clinics.支气管扩张症门诊的细菌传播风险
Curr Pulmonol Rep. 2018;7(3):72-78. doi: 10.1007/s13665-018-0203-6. Epub 2018 Jul 2.
10
Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone.铜绿假单胞菌突变耐药组在国际囊性纤维化克隆中的演变。
Sci Rep. 2017 Jul 17;7(1):5555. doi: 10.1038/s41598-017-05621-5.